Authors:
STAKHOVSKAYA L.V.*1, TYUTYUMOVA E.A.2*, FEDIN A.I.*2
1*Research Institute of Cerebrovascular Pathology and Stroke,
N.I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia;
2*Federal State Budgetary Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russia
Place of publication:
JOURNAL OF NEUROLOGY AND PSYCHIATRY, 8, 2017
The article presents the results of a series of domestic clinical trials examining the efficacy and safety of Mexidol in patients with cerebrovascular disorders, particularly ischemic stroke (IS). It is emphasized that Mexidol use is associated with more complete and rapid regression of focal neurological deficits. Mexidol treatment is well tolerated and has no significant adverse effects. Enteral and parenteral administration of the drug are recommended for patients with IS.
Keywords: ischemic stroke, treatment, Mexidol.